DK1499730T3 - Immunokonjugater til behandling af tumorer - Google Patents

Immunokonjugater til behandling af tumorer

Info

Publication number
DK1499730T3
DK1499730T3 DK03725526.2T DK03725526T DK1499730T3 DK 1499730 T3 DK1499730 T3 DK 1499730T3 DK 03725526 T DK03725526 T DK 03725526T DK 1499730 T3 DK1499730 T3 DK 1499730T3
Authority
DK
Denmark
Prior art keywords
immunoconjugates
tumors
treatment
Prior art date
Application number
DK03725526.2T
Other languages
English (en)
Inventor
Angelo Corti
Flavio Curnis
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molmed Spa filed Critical Molmed Spa
Application granted granted Critical
Publication of DK1499730T3 publication Critical patent/DK1499730T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
DK03725526.2T 2002-04-30 2003-04-30 Immunokonjugater til behandling af tumorer DK1499730T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0209896A GB0209896D0 (en) 2002-04-30 2002-04-30 Conjugate
PCT/IB2003/002187 WO2003093478A1 (en) 2002-04-30 2003-04-30 Immunoconjugates for the treatment of tumours

Publications (1)

Publication Number Publication Date
DK1499730T3 true DK1499730T3 (da) 2014-01-13

Family

ID=9935816

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03725526.2T DK1499730T3 (da) 2002-04-30 2003-04-30 Immunokonjugater til behandling af tumorer

Country Status (19)

Country Link
US (3) US20050033026A1 (da)
EP (1) EP1499730B1 (da)
JP (1) JP4656937B2 (da)
KR (1) KR20050007359A (da)
CN (1) CN1665933B (da)
AU (1) AU2003228057B2 (da)
CA (1) CA2462879A1 (da)
CY (1) CY1114730T1 (da)
DK (1) DK1499730T3 (da)
EA (1) EA007396B1 (da)
ES (1) ES2441193T3 (da)
GB (1) GB0209896D0 (da)
HK (1) HK1072443A1 (da)
IL (1) IL164896A (da)
NO (1) NO332827B1 (da)
PT (1) PT1499730E (da)
SI (1) SI1499730T1 (da)
WO (1) WO2003093478A1 (da)
ZA (1) ZA200408767B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066348A2 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
CN101124243A (zh) * 2004-12-23 2008-02-13 莫尔梅德股份有限公司 缀合产物
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
KR100835879B1 (ko) * 2006-10-10 2008-06-09 학교법인 한림대학교 아넥신 융합 단백질
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
GB0708864D0 (en) * 2007-05-08 2007-06-13 Molmed Spa Cytokine Conjugate
MX2009013752A (es) * 2007-06-28 2010-02-01 Philogen Spa Inmunocitocinas para el tratamiento del cancer en combinacion con agentes quimioterapeuticos.
SI2209805T1 (sl) * 2007-10-30 2017-11-30 Philogen S.P.A. Antigen, povezan z revmatoidnim artritisom
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
NO2297304T3 (da) * 2008-05-07 2018-02-10
UA107921C2 (en) 2008-11-26 2015-03-10 Amgen Inc Variants of polypeptide of receptor ivr activin and their use
CA2747154C (en) * 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
US8877889B2 (en) * 2009-09-02 2014-11-04 Industry-Academic Cooperation Foundation, Chosun University Tumor cell-killing peptides
US20150359850A1 (en) 2009-11-25 2015-12-17 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
KR20140108562A (ko) 2011-12-19 2014-09-11 암젠 인코퍼레이티드 변이체 액티빈 수용체 폴리펩티드 단독 또는 화학 치료법과의 결합, 및 그들의 용도
EP2850201A4 (en) * 2012-05-11 2016-08-31 Alexander Krantz Site-specific labeling and targeted administration of proteins for the treatment of cancer
HUE044927T2 (hu) 2012-10-03 2019-11-28 Philogen Spa Ellenanyag-konjugátum, gyulladásos bélbetegség kezelésében történõ alkalmazásra
TWI602577B (zh) * 2015-08-27 2017-10-21 國立陽明大學 雙重標靶融合蛋白
CN105622759A (zh) * 2016-01-04 2016-06-01 深圳精准医疗科技有限公司 IL-12/CD107a融合蛋白增强CTL抗肿瘤效果的治疗剂及其制法和用途
WO2017194782A2 (en) * 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CA3039573A1 (en) * 2016-10-05 2018-04-12 Acceleron Pharma Inc. Alk4:actriib heteromultimers and uses thereof
EP3886913A4 (en) * 2018-11-30 2023-01-11 Prism | Proteogenomics Research Institute for Systems Medicine IMPROVED TARGETED DELIVERY OF THERAPEUTICS
CN117683140A (zh) * 2022-09-09 2024-03-12 北京昌平实验室 肿瘤靶向的以白介素2为活性成分的融合蛋白型药物前体

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4879237A (en) * 1985-05-24 1989-11-07 La Jolla Cancer Research Foundation Use of peptides in control of cell attachment and detachment
US4988621A (en) * 1985-05-24 1991-01-29 La Jolla Cancer Research Foundation Peptides in cell detachment and aggregation
US5547936A (en) * 1985-06-17 1996-08-20 La Jolla Cancer Research Foundation Inhibition of cell migration with synthetic peptides
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
DE3716513A1 (de) * 1987-05-16 1988-11-24 Basf Ag Proteine mit tnf-wirkung
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
AU5342290A (en) 1989-03-15 1990-10-09 David R. Kaplan Cd8-based pharmaceuticals
US5120829A (en) * 1989-03-20 1992-06-09 La Jolla Cancer Research Foundation Hydrophobic attachment site for adhesion peptides
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5498694A (en) * 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5648330A (en) * 1990-04-06 1997-07-15 La Jolla Cancer Research Foundation Method and composition for treating vascular graft occlusion
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
ATE218889T1 (de) * 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
CA2178476A1 (en) 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
JP2820016B2 (ja) 1993-12-28 1998-11-05 日本電気株式会社 電子回路
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
JPH11505805A (ja) 1995-05-16 1999-05-25 プリズム ファーマシューティカルズ，インコーポレイテッド 治療的処置のための核酸およびリガンドを含有する組成物
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
UY24367A1 (es) 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
US6576239B1 (en) * 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
DE69734887T2 (de) 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
US6759509B1 (en) * 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
DE69839844D1 (de) 1997-09-10 2008-09-18 Burnham Inst Verfahren zur auffindung von zielsuchenden verbindungen spezifisch für angiogenese vaskulatur
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
WO2000009143A1 (en) * 1998-08-13 2000-02-24 G.D. Searle & Co. Multivalent avb3 and metastasis-associated receptor ligands
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
US7309694B2 (en) * 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
PT1719528E (pt) * 2000-02-24 2012-01-06 Philogen Spa Composições e métodos para tratamento de angiogénese em lesões patológicas
WO2001090326A2 (en) * 2000-05-22 2001-11-29 Pharmacia & Upjohn Company Novel matrix metalloproteinases
CA2414650A1 (en) * 2000-06-30 2002-01-10 Board Of Regents, The University Of Texas System Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
EP1217070A1 (en) 2000-12-22 2002-06-26 CellGenix Technologie Transfer GmbH Selective cytotoxic fusion proteins
US20030077818A1 (en) * 2001-03-08 2003-04-24 Dickerson Erin B. Compositions and methods for targeting interleukin-12 to malignant endothelium
AU2003272511A1 (en) * 2002-09-13 2004-04-30 Dyax Corporation Cd44-binding ligands

Also Published As

Publication number Publication date
US9782496B2 (en) 2017-10-10
CY1114730T1 (el) 2016-10-05
NO20045237L (no) 2005-01-28
EP1499730A1 (en) 2005-01-26
NO332827B1 (no) 2013-01-21
AU2003228057B2 (en) 2008-08-28
EA007396B1 (ru) 2006-10-27
HK1072443A1 (en) 2005-08-26
CN1665933A (zh) 2005-09-07
US20100310506A1 (en) 2010-12-09
ES2441193T3 (es) 2014-02-03
ZA200408767B (en) 2006-12-27
US9119886B2 (en) 2015-09-01
SI1499730T1 (sl) 2014-02-28
WO2003093478A9 (en) 2004-12-09
CA2462879A1 (en) 2003-11-13
AU2003228057A1 (en) 2003-11-17
US20160074537A1 (en) 2016-03-17
JP4656937B2 (ja) 2011-03-23
JP2005526117A (ja) 2005-09-02
US20050033026A1 (en) 2005-02-10
EP1499730B1 (en) 2013-10-02
CN1665933B (zh) 2010-05-26
GB0209896D0 (en) 2002-06-05
PT1499730E (pt) 2013-12-17
WO2003093478A1 (en) 2003-11-13
KR20050007359A (ko) 2005-01-17
IL164896A (en) 2012-04-30
IL164896A0 (en) 2005-12-18
EA200401446A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
NO20052914D0 (no) Terapeutiske forbindelser
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
NO20035156D0 (no) Fremgangsmåter for brönnbehandling
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1176964T3 (da) Brug af ET743 til behandling af cancer
NO20033205D0 (no) Terapeutiske kromanforbindelser
NO20045554L (no) Fremgangsmate for behandling av diabetes
DK1596870T4 (da) Højdosis-ibandronatformulering
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DK1350521T3 (da) Immunoterapeutiske kombinationer til behandling af tumorer
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme